These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 31605106

  • 1. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
    O'Reilly EM, Hechtman JF.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
    [Abstract] [Full Text] [Related]

  • 2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.
    Lancet Oncol; 2018 May 01; 19(5):705-714. PubMed ID: 29606586
    [Abstract] [Full Text] [Related]

  • 3. Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
    Gupta M, Sherrow C, Krone ME, Blais EM, Pishvaian MJ, Petricoin EF, Matrisian LM, DeArbeloa P, Gregory G, Brown A, Zalewski O, Prinzing G, Roche C, Kanehira K, Mukherjee S, Iyer R, Fountzilas C.
    J Natl Compr Canc Netw; 2021 Jan 06; 19(1):10-15. PubMed ID: 33406492
    [Abstract] [Full Text] [Related]

  • 4. Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma.
    Goh XN, Seng MS, Loh AHP, Gupta A, Chang KTE, Iyer P.
    J Oncol Pharm Pract; 2021 Mar 06; 27(2):485-489. PubMed ID: 32693686
    [Abstract] [Full Text] [Related]

  • 5. Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
    Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, Guzman S, Tuch BB, Ebata K, de Stanchina E, Nagy RJ, Lanman RB, Houck-Loomis B, Patel JA, Berger MF, Ladanyi M, Hyman DM, Drilon A, Scaltriti M.
    Nat Med; 2019 Sep 06; 25(9):1422-1427. PubMed ID: 31406350
    [Abstract] [Full Text] [Related]

  • 6. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
    Zhang L, Liu H, Tian Y, Wang H, Yang X.
    BMC Pulm Med; 2021 Apr 17; 21(1):125. PubMed ID: 33865348
    [Abstract] [Full Text] [Related]

  • 7. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E, Scaltriti M, Drilon A.
    Nat Rev Clin Oncol; 2018 Dec 17; 15(12):731-747. PubMed ID: 30333516
    [Abstract] [Full Text] [Related]

  • 8. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE, Park CK, Kim SK, Phi JH, Paek SH, Choi JY, Kang HJ, Lee JH, Won JK, Yun H, Park SH.
    Acta Neuropathol Commun; 2024 Jul 16; 12(1):118. PubMed ID: 39014476
    [Abstract] [Full Text] [Related]

  • 9. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.
    Br J Cancer; 2024 Aug 16; 131(3):601-610. PubMed ID: 38902532
    [Abstract] [Full Text] [Related]

  • 10. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N, McDermott R.
    Expert Rev Clin Pharmacol; 2019 Oct 16; 12(10):931-939. PubMed ID: 31469968
    [Abstract] [Full Text] [Related]

  • 11. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
    Bielack SS, Cox MC, Nathrath M, Apel K, Blattmann C, Holl T, Jenewein R, Klenk U, Klothaki P, Müller-Abt P, Ortega-Lawerenz S, Reynolds M, Scheer M, Simon-Klingenstein K, Stegmaier S, Tupper R, Vokuhl C, von Kalle T.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
    [Abstract] [Full Text] [Related]

  • 12. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW.
    Cancer; 2023 Dec 01; 129(23):3772-3782. PubMed ID: 37769113
    [Abstract] [Full Text] [Related]

  • 13. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 14. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y, Kawano M, Iwasaki T, Itonaga I, Tsumura H, Kaku N, Tanaka K.
    Medicine (Baltimore); 2023 Dec 08; 102(49):e36232. PubMed ID: 38065851
    [Abstract] [Full Text] [Related]

  • 15. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
    Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC.
    Ann Oncol; 2019 Feb 01; 30(2):325-331. PubMed ID: 30624546
    [Abstract] [Full Text] [Related]

  • 16. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, López-Ríos F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J.
    BMC Cancer; 2022 Jun 07; 22(1):625. PubMed ID: 35672677
    [Abstract] [Full Text] [Related]

  • 17. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F, Rudzinski ER, Sepulveda AR.
    J Clin Pathol; 2019 Jul 07; 72(7):460-467. PubMed ID: 31072837
    [Abstract] [Full Text] [Related]

  • 18. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF, Demetri GD.
    Future Oncol; 2020 Mar 07; 16(9):417-425. PubMed ID: 32129093
    [Abstract] [Full Text] [Related]

  • 19. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
    Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
    [Abstract] [Full Text] [Related]

  • 20. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
    Klink AJ, Kavati A, Gassama A, Kozlek T, Gajra A, Antoine R.
    Target Oncol; 2022 Sep 01; 17(5):549-561. PubMed ID: 36089643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.